332 related articles for article (PubMed ID: 27534668)
21. New Hydrophilic Matrix Tablets for the Controlled Released of Chlorzoxazone.
Creteanu A; Lisa G; Vasile C; Popescu MC; Pamfil D; Lungu CN; Panainte AD; Tantaru G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791175
[TBL] [Abstract][Full Text] [Related]
22. Formulation and evaluation of Cetirizine dihydrochloride orodispersible tablet.
Subramanian S; Sankar V; Manakadan AA; Ismail S; Andhuvan G
Pak J Pharm Sci; 2010 Apr; 23(2):232-5. PubMed ID: 20363705
[TBL] [Abstract][Full Text] [Related]
23. Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-masking agent in dextromethorphan hydrobromide orally disintegrating tablets.
Mahrous GM; Ibrahim MA; Mostafa HF; Elzayat EM
Pharm Dev Technol; 2019 Jul; 24(6):711-719. PubMed ID: 30714850
[TBL] [Abstract][Full Text] [Related]
24. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
[TBL] [Abstract][Full Text] [Related]
25. The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
Krupa A; Jachowicz R; Pędzich Z; Wodnicka K
AAPS PharmSciTech; 2012 Dec; 13(4):1120-9. PubMed ID: 22941425
[TBL] [Abstract][Full Text] [Related]
26. Further improvement of orally disintegrating tablets using micronized ethylcellulose.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608
[TBL] [Abstract][Full Text] [Related]
27. Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone.
Tranová T; Loskot J; Navrátil O; Brniak W; Mužíková J
Int J Pharm; 2023 Apr; 636():122838. PubMed ID: 36921743
[TBL] [Abstract][Full Text] [Related]
28. Assessment of oral formulation-dependent characteristics of orodispersible tablets using texture profiles and multivariate data analysis.
Casian T; Bogdan C; Tarta D; Moldovan M; Tomuta I; Iurian S
J Pharm Biomed Anal; 2018 Apr; 152():47-56. PubMed ID: 29414018
[TBL] [Abstract][Full Text] [Related]
29. Novel levocetirizine HCl tablets with enhanced palatability: synergistic effect of combining taste modifiers and effervescence technique.
Labib GS
Drug Des Devel Ther; 2015; 9():5135-46. PubMed ID: 26379426
[TBL] [Abstract][Full Text] [Related]
30. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression.
Kande KV; Kotak DJ; Degani MS; Kirsanov D; Legin A; Devarajan PV
AAPS PharmSciTech; 2017 Aug; 18(6):2055-2066. PubMed ID: 27995465
[TBL] [Abstract][Full Text] [Related]
31. Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants.
Sheshala R; Khan N; Chitneni M; Darwis Y
Arch Pharm Res; 2011 Nov; 34(11):1945-56. PubMed ID: 22139694
[TBL] [Abstract][Full Text] [Related]
32. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
Tafere C; Yilma Z; Abrha S; Yehualaw A
PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
[TBL] [Abstract][Full Text] [Related]
34. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
[TBL] [Abstract][Full Text] [Related]
35. Formulation and evaluation of taste-masked levocetirizine dihydrochloride orally disintegrating tablets.
Devireddy SR; Gonugunta CS; Veerareddy PR
PDA J Pharm Sci Technol; 2009; 63(6):521-6. PubMed ID: 20169858
[TBL] [Abstract][Full Text] [Related]
36. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets.
Douroumis DD; Gryczke A; Schminke S
AAPS PharmSciTech; 2011 Mar; 12(1):141-51. PubMed ID: 21181510
[TBL] [Abstract][Full Text] [Related]
37. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
Cantor SL; Khan MA; Gupta A
Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
[TBL] [Abstract][Full Text] [Related]
38. Application of SeDeM expert systems in preformulation studies of pediatric ibuprofen ODT tablets.
Sipos E; Oltean AR; Szabó ZI; Rédai EM; Nagy GD
Acta Pharm; 2017 Jun; 67(2):237-246. PubMed ID: 28590910
[TBL] [Abstract][Full Text] [Related]
39. Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.
Gulsun T; Ozturk N; Kaynak MS; Vural I; Sahin S
Pharmazie; 2017 Jul; 72(7):389-394. PubMed ID: 29441935
[TBL] [Abstract][Full Text] [Related]
40. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
